Résumé
Non-VKA oral anticoagulants (NOACs), thanks to their ease of use and their similar or superior safety/efficacy profiles versus warfarin, have now widely reached the lucrative market of anticoagulation. However, while the marketing authorization holders always claim, in a quite unclear way that no monitoring is required, accumulative evidence and cases of major bleeding have been described in the literature and reported by spontaneous reporting systems at the regulator's level. These compounds are usually given at fixed doses without routine coagulation monitoring. However, new data suggests that an assessment of the response at the individual level could improve the benefit-risk ratio of, at least dabigatran. Therefore, in certain patient populations, i.e. acute or chronic renal impairment or multiple drug interactions, measurement of drug exposure may be useful to ensure an optimal treatment response. More specific circumstances such as patients experiencing a haemorrhagic or thromboembolic event during the treatment duration, patients who require urgent surgery or an invasive procedure, or patient with a suspected overdose could benefit from such a measurement. This article aims at providing guidance on how to best estimate the intensity of anticoagulation using laboratory assays in daily practice.
Titre traduit de la contribution | Non-VKA oral anticoagulants: An update for the clinical biologists |
---|---|
langue originale | Français |
Pages (de - à) | 333-344 |
Nombre de pages | 12 |
journal | Annales de biologie clinique |
Volume | 73 |
Numéro de publication | 3 |
Les DOIs | |
Etat de la publication | Publié - 1 mai 2015 |
Empreinte digitale
Examiner les sujets de recherche de « Anticoagulants directs oraux: Actualités pour les biologistes ». Ensemble, ils forment une empreinte digitale unique.Thèses de l'étudiant
-
Evaluation of thrombotic and/or bleeding risks associated with anticoagulotherapy.
Auteur: Douxfils, J., 24 oct. 2015Superviseur: Dogne, J. (Promoteur), Mullier, F. (Promoteur), Masereel, B. (Président), Chatelain, B. (Jury), Chatelain, C. (Personne externe) (Jury), Verhamme, P. B. (Personne externe) (Jury), TEN CATE, H. (Personne externe) (Jury) & Ageno, W. (Personne externe) (Jury)
Student thesis: Doc types › Docteur en Sciences Biomédicales et Pharmaceutiques